STOCK TITAN

LifeStance Health Group (LFST): TPG entities disclose 98.1M-share, 25.7% ownership

(Neutral)
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

LifeStance Health Group, Inc. has a significant shareholder group led by TPG GP A, LLC, together with James G. Coulter and Jon Winkelried as reporting persons. Through TPG VIII Lynnwood Holdings Aggregation, L.P., they report beneficial ownership of 98,101,407 shares of common stock.

This represents 25.7% of LifeStance’s common stock, based on 382,055,609 shares outstanding as of July 29, 2026. The shares are held indirectly through a chain of TPG entities, with voting and dispositive power shared among the reporting persons, who each disclaim beneficial ownership beyond their pecuniary interest.

Positive

  • None.

Negative

  • None.
Shares beneficially owned 98,101,407 shares Common Stock beneficially owned indirectly by TPG VIII Lynnwood and reporting persons
Percent of class 25.7% Ownership percentage of LifeStance common stock based on shares outstanding as of July 29, 2026
Shares outstanding baseline 382,055,609 shares LifeStance common stock outstanding as of July 29, 2026, from Form 10-Q
Shared voting power 98,101,407 shares Shares over which the reporting persons have shared power to vote or direct the vote
Shared dispositive power 98,101,407 shares Shares over which the reporting persons have shared power to dispose or direct disposition
beneficial owner regulatory
"may be deemed to be the beneficial owner of the shares of Common Stock"
A beneficial owner is the person who ultimately owns or controls a financial asset or property, even if their name isn't directly on official documents. Think of it like someone who secretly holds the keys to a safe deposit box—others may appear to have access, but the true owner is the one who benefits from what's inside. Identifying beneficial owners helps ensure transparency and prevent illegal activities like money laundering or fraud.
Schedule 13G regulatory
"Amendment No. 3 to is being filed jointly ... under the Act"
A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.
Stockholders Agreement regulatory
"TPG VIII Lynnwood entered into a Stockholders Agreement, dated as of June 9, 2021"
pecuniary interest financial
"disclaim beneficial ownership of such shares of Common Stock ... except to the extent of their pecuniary interest"
group regulatory
"may be deemed, pursuant to Rule 13d-3 under the Act, to beneficially own ... and/or to constitute a "group""

FAQ

What ownership stake in LFST does TPG GP A, LLC report in this Schedule 13G/A?

TPG GP A, LLC, together with related entities, reports beneficial ownership of 98,101,407 shares of LifeStance Health Group, Inc. common stock, representing 25.7% of the company’s outstanding shares based on 382,055,609 shares outstanding as of July 29, 2026.

How many LifeStance Health (LFST) shares are outstanding for this ownership calculation?

The reported 25.7% ownership stake is calculated using 382,055,609 shares of LifeStance Health Group, Inc. common stock outstanding as of July 29, 2026, as referenced from the company’s Quarterly Report on Form 10-Q filed on August 6, 2026.

Do James G. Coulter and Jon Winkelried personally own 25.7% of LFST?

James G. Coulter and Jon Winkelried may be deemed beneficial owners of 98,101,407 shares through TPG entities but disclaim beneficial ownership except to the extent of their pecuniary interest. The shares are held indirectly via TPG VIII Lynnwood Holdings Aggregation, L.P.

What voting and dispositive powers over LFST shares do the reporting persons have?

The reporting persons state 0 shares with sole voting or dispositive power and 98,101,407 shares with shared voting and shared dispositive power. This reflects coordinated control through TPG VIII Lynnwood and related TPG entities rather than individual direct control.

How does the Stockholders Agreement affect TPG’s influence over LFST?

TPG VIII Lynnwood has a Stockholders Agreement with other holders to vote their LFST shares for board elections as specified. As a result, the reporting persons may be deemed part of a group, potentially extending their influence, though they disclaim beneficial ownership of other holders’ shares beyond any pecuniary interest.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates





53228F101

(CUSIP Number)
06/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: The percentage beneficial ownership set forth in response to Item 11 above is based on 382,055,609 shares of Common Stock (as defined below) outstanding as of July 29, 2026, as reported on the Quarterly Report on Form 10-Q filed by LifeStance Health Group, Inc. (the "Issuer") with the Securities and Exchange Commission (the "Commission") on August 6, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person: The percentage beneficial ownership set forth in response to Item 11 above is based on 382,055,609 shares of Common Stock outstanding as of July 29, 2026, as reported on the Quarterly Report on Form 10-Q filed by the Issuer with the Commission on August 6, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person: The percentage beneficial ownership set forth in response to Item 11 above is based on 382,055,609 shares of Common Stock outstanding as of July 29, 2026, as reported on the Quarterly Report on Form 10-Q filed by the Issuer with the Commission on August 6, 2026.


SCHEDULE 13G



TPG GP A, LLC
Signature:/s/ Matthew White
Name/Title:Matthew White / Vice President
Date:08/14/2026
COULTER, JAMES G
Signature:/s/ Gerald Neugebauer
Name/Title:Gerald Neugebauer on behalf of James G. Coulter (1)
Date:08/14/2026
WINKELRIED, JON
Signature:/s/ Gerald Neugebauer
Name/Title:Gerald Neugebauer on behalf of Jon Winkelried (2)
Date:08/14/2026

Comments accompanying signature: (1) Gerald Neugebauer is signing on behalf of Mr. Coulter pursuant to an authorization and designation letter dated January 10, 2024, which was previously filed with the Commission as an exhibit to a Form 4 filed by Mr. Coulter on February 7, 2024 (SEC File No. 001-41617). (2) Gerald Neugebauer is signing on behalf of Mr. Winkelried pursuant to an authorization and designation letter dated January 10, 2024, which was previously filed with the Commission as an exhibit to a Form 4 filed by Mr. Winkelried on February 7, 2024 (SEC File No. 001-41617).
Exhibit Information

Exhibit 1 Agreement of Joint Filing as required by Rule 13d-1(k)(1) under the Act.* * Incorporated herein by reference to the Agreement of Joint Filing by TPG Group Holdings (SBS) Advisors, Inc., TPG GP A, LLC, TPG Advisors VII, Inc., TPG Advisors VI, Inc., TPG Advisors VI-AIV, Inc., TPG Asia Advisors VI, Inc., David Bonderman, James G. Coulter, Jon Winkelried and Karl Peterson dated as of January 18, 2022, which was previously filed with the Securities and Exchange Commission (the "Commission") as Exhibit 1 to Amendment No. 4 to Schedule 13D filed by TPG GP A, LLC, David Bonderman, James G. Coulter and Jon Winkelried on January 18, 2022 with respect to the shares of common stock of Allogene Therapeutics, Inc.